Navigation Links
YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Date:2/13/2009

ioSciences

YM BioSciences Inc. is a therapeutic product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM's proven regulatory and clinical trial expertise allows for the effective advancement of its products with reduced risk, via a diversified business model, towards approval and commercialization worldwide.

Nimotuzumab is in development targeting multiple tumor types in combination with radiation, chemoradiation and chemotherapy. The humanized monoclonal antibody, which is approved for marketing in twelve of countries, is significantly differentiated from all other EGFR-targeting agents because of a remarkably benign side-effect profile. In more than 3,500 patients reported as having been treated worldwide to date, no Grade III/IV incidents of rash or Grade IV radiation dermatitis haves been reported, and any of the other side-effects that are typical of EGFR-targeting molecules have been rare. YM is developing AeroLEF(R) for the treatment of moderate to severe acute pain. The product completed a randomized Phase II trial and is being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishme
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
2. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
3. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
5. BD Biosciences to Distribute FCS Express
6. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
7. Cell Biosciences Introduces Kits for Oncoprotein Analysis
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... International, a leading provider of regulatory compliance, quality systems, analytical testing, education ... a consulting firm with expertise in medical device products/processes development, design control, ...
(Date:9/2/2015)... ... 2015 , ... The wet form of macular degeneration, although ... growth factor agents given by injection into the eye. Dry macular degeneration (AMD) ... for the many millions diagnosed with it. AMD usually starts in older age ...
(Date:9/2/2015)... , Sep. 02, 2015 ... ) has announced the addition of Jain ... Markets and Companies" to their offering. ... several technologies besides fluorescence in situ hybridization ... FISH. Molecular cytogenetics includes application of nanobiotechnology, ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... everyday products from computers to shampoo can adversely affect the ... Research by the University of Edinburgh suggests that industrial manufacturers ... types of nanoparticles pose to workers who handle them. ... width of a human hair are potentially hazardous to ...
... smaller the need to understand nanoscale phenomena becomes greater ... nanoscale than they do at larger scales, new techniques ... phenomena. A team of researchers led by Paul Weiss, ... a tool to study nanoscale interactions. Their device is ...
... DIEGO, Nov. 17, 2010 Nanotrope, Inc. announced today ... covering its ground-breaking diagnostic test for influenza and other ... that creates an artificial "cell" engineered with specific membrane ... infecting the mimic as it would a normal host ...
Cached Biology Technology:Nanoscale probe reveals interactions between surfaces and single molecules 2Nanotrope, Inc. Receives Patent on New Diagnostic Test for Influenza and Other Viral Infections 2
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... scientists to monitor how individual cells react in the complex ... much larger spectrum of differences between each cell than ever ... fashion, as was previously thought. "Think of cells as ... professor of bioengineering and senior author of the study, which ...
... June 26 Consuming higher amounts of omega-3 fatty ... for women with type 1 diabetes, according to a ... being presented at the 70th Scientific Sessions of the ... included 601 men and women enrolled in the Pittsburgh ...
... plant diversity in a forest? It,s a question even ... forest diversity demonstrates only patterns of species survival and ... now. A team of researchers led by biologists ... soil-borne pathogens are one important mechanism that can maintain ...
Cached Biology News:Same types of cell respond differently to stimulus, Stanford study shows 2Same types of cell respond differently to stimulus, Stanford study shows 3Soil-borne pathogens drive tree diversity in forests, study shows 2
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
... bench time to just 15 minutes! The ... that can be drawn between this exciting new ... instant foods. Instant meals consumed by astronauts, ... and are reconstituted by adding water. The ...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Candida (IgA) -Ab EIA Sample Size: 5 l...
Biology Products: